In OI, mutations in collagen I and alterations of the ECM lead to abnormal release and activation of TGF-β, resulting in enhanced TGF-β signaling that contributes to impaired bone formation and increased bone fragility [93,326]. This evidence concerns the gene TGFB1 and osteogenesis imperfecta.